These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38490364)

  • 41. A systematic review of contralateral liver lobe hypertrophy after unilobar selective internal radiation therapy with Y90.
    Teo JY; Allen JC; Ng DC; Choo SP; Tai DW; Chang JP; Cheah FK; Chow PK; Goh BK
    HPB (Oxford); 2016 Jan; 18(1):7-12. PubMed ID: 26776845
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Radiation dose limits and liver toxicities resulting from multiple yttrium-90 radioembolization treatments for hepatocellular carcinoma.
    Young JY; Rhee TK; Atassi B; Gates VL; Kulik L; Mulcahy MF; Larson AC; Ryu RK; Sato KT; Lewandowski RJ; Omary RA; Salem R
    J Vasc Interv Radiol; 2007 Nov; 18(11):1375-82. PubMed ID: 18003987
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Volumetric changes after (90)y radioembolization for hepatocellular carcinoma in cirrhosis: an option to portal vein embolization in a preoperative setting?
    Edeline J; Lenoir L; Boudjema K; Rolland Y; Boulic A; Le Du F; Pracht M; Raoul JL; Clément B; Garin E; Boucher E
    Ann Surg Oncol; 2013 Aug; 20(8):2518-25. PubMed ID: 23494107
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Radioembolization with Yttrium-90 Glass Microspheres as a First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma-A Prospective Feasibility Study.
    Kis B; Shridhar R; Mhaskar R; Gyano M; Frakes JM; El-Haddad G; Choi J; Kim RD; Hoffe SE
    J Vasc Interv Radiol; 2023 Sep; 34(9):1547-1555. PubMed ID: 37210030
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Yttrium-90 Radioembolization as a Salvage Treatment following Chemoembolization for Hepatocellular Carcinoma.
    Johnson GE; Monsky WL; Valji K; Hippe DS; Padia SA
    J Vasc Interv Radiol; 2016 Aug; 27(8):1123-9. PubMed ID: 27321889
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety and Efficacy of Segmental Yttrium-90 Radioembolization for Hepatocellular Carcinoma after Transjugular Intrahepatic Portosystemic Shunt Creation.
    Gordon AC; Gupta AN; Gabr A; Thornburg BG; Kulik LM; Ganger DR; Maddur H; Flamm SL; Boike JR; Moore CM; Borja-Cacho D; Christopher DA; Katariya NN; Ladner DP; Caicedo-Ramirez JC; Riaz A; Salem R; Lewandowski RJ
    J Vasc Interv Radiol; 2021 Feb; 32(2):211-219. PubMed ID: 33349507
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Outcomes of Radioembolization in the Treatment of Hepatocellular Carcinoma with Portal Vein Invasion: Resin versus Glass Microspheres.
    Biederman DM; Titano JJ; Tabori NE; Pierobon ES; Alshebeeb K; Schwartz M; Facciuto ME; Gunasekaran G; Florman S; Fischman AM; Patel RS; Nowakowski FS; Kim E
    J Vasc Interv Radiol; 2016 Jun; 27(6):812-821.e2. PubMed ID: 27062356
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study.
    Salem R; Johnson GE; Kim E; Riaz A; Bishay V; Boucher E; Fowers K; Lewandowski R; Padia SA
    Hepatology; 2021 Nov; 74(5):2342-2352. PubMed ID: 33739462
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety of Combined Yttrium-90 Radioembolization and Immune Checkpoint Inhibitor Immunotherapy for Hepatocellular Carcinoma.
    Zhan C; Ruohoniemi D; Shanbhogue KP; Wei J; Welling TH; Gu P; Park JS; Dagher NN; Taslakian B; Hickey RM
    J Vasc Interv Radiol; 2020 Jan; 31(1):25-34. PubMed ID: 31422022
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Yttrium-90 radioembolization as a bridge to liver transplantation: a single-institution experience.
    Tohme S; Sukato D; Chen HW; Amesur N; Zajko AB; Humar A; Geller DA; Marsh JW; Tsung A
    J Vasc Interv Radiol; 2013 Nov; 24(11):1632-8. PubMed ID: 24160821
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A comparative study of portal vein embolization versus radiation lobectomy with Yttrium-90 micropheres in preparation for liver resection for initially unresectable hepatocellular carcinoma.
    Bekki Y; Marti J; Toshima T; Lewis S; Kamath A; Argiriadi P; Simpson W; Facciuto L; Patel RS; Gunasekaran G; Kim E; Schiano TD; Facciuto ME
    Surgery; 2021 May; 169(5):1044-1051. PubMed ID: 33648768
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dosimetric parameters predicting contralateral liver hypertrophy after unilobar radioembolization of hepatocellular carcinoma.
    Palard X; Edeline J; Rolland Y; Le Sourd S; Pracht M; Laffont S; Lenoir L; Boudjema K; Ugen T; Brun V; Mesbah H; Haumont LA; Loyer P; Garin E
    Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):392-401. PubMed ID: 29177870
    [TBL] [Abstract][Full Text] [Related]  

  • 53. ALPPS for primary and secondary liver tumors.
    Vennarecci G; Grazi GL; Sperduti I; Busi Rizzi E; Felli E; Antonini M; D'Offizi G; Ettorre GM
    Int J Surg; 2016 Jun; 30():38-44. PubMed ID: 27112834
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Yttrium-90 Radioembolization Is Cost Effective in Intrahepatic Cholangiocarcinoma: A SEER Medicare Population Study.
    Ghodadra A; Xing M; Zhang D; Kim HS
    J Vasc Interv Radiol; 2019 Mar; 30(3):293-297. PubMed ID: 30819468
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.
    Hong TS; Wo JY; Yeap BY; Ben-Josef E; McDonnell EI; Blaszkowsky LS; Kwak EL; Allen JN; Clark JW; Goyal L; Murphy JE; Javle MM; Wolfgang JA; Drapek LC; Arellano RS; Mamon HJ; Mullen JT; Yoon SS; Tanabe KK; Ferrone CR; Ryan DP; DeLaney TF; Crane CH; Zhu AX
    J Clin Oncol; 2016 Feb; 34(5):460-8. PubMed ID: 26668346
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Temporary Balloon Occlusion for Hepatic Arterial Flow Redistribution during Yttrium-90 Radioembolization.
    Meek J; Fletcher S; Gauss CH; Bezold S; Borja-Cacho D; Meek M
    J Vasc Interv Radiol; 2019 Aug; 30(8):1201-1206. PubMed ID: 31155499
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Neoadjuvant Radiation Lobectomy As an Alternative to Portal Vein Embolization in Hepatocellular Carcinoma.
    Gabr A; Polineni P; Mouli SK; Riaz A; Lewandowski RJ; Salem R
    Semin Nucl Med; 2019 May; 49(3):197-203. PubMed ID: 30954185
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Left-liver hypertrophy after therapeutic right-liver radioembolization is substantial but less than after portal vein embolization.
    Garlipp B; de Baere T; Damm R; Irmscher R; van Buskirk M; Stübs P; Deschamps F; Meyer F; Seidensticker R; Mohnike K; Pech M; Amthauer H; Lippert H; Ricke J; Seidensticker M
    Hepatology; 2014 May; 59(5):1864-73. PubMed ID: 24259442
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Yttrium-90 Radioembolization for Hepatocellular Carcinoma with Portal Vein Invasion: Validation of the Milan Prognostic Score.
    Bargellini I; Scalise P; Boni G; Traino CA; Bozzi E; Lorenzoni G; Crocetti L; Cioni R
    J Vasc Interv Radiol; 2020 Dec; 31(12):2028-2032. PubMed ID: 33121865
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Transarterial radioembolization versus chemoembolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial.
    Seinstra BA; Defreyne L; Lambert B; Lam MG; Verkooijen HM; van Erpecum KJ; van Hoek B; van Erkel AR; Coenraad MJ; Al Younis I; van Vlierberghe H; van den Bosch MA
    Trials; 2012 Aug; 13():144. PubMed ID: 22913492
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.